Results 201 to 210 of about 241,142 (235)
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source
Gastric cancer‐derived exosomal TAGLN2 is identified as a key mediator of vascular reprogramming, with significantly elevated levels detected in patient serum. Independent of canonical SEMA4D signaling, it nucleates a cytoplasmic TAGLN2/NRP1/SEMA4D ternary complex that dually activates YAP, promoting angiogenesis, vascular dysfunction, and metastasis ...
Shuqi Yu +7 more
wiley +1 more source
Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]
Bartlett, Nancy L +2 more
core +2 more sources
This work proposes a multifunctional Bi2WO6:Yb,Er@CuS@CS nanocomposite that integrates photodynamic therapy (PDT), near‐infrared‐triggered photothermal therapy (PTT), and Cu2+ release for infected wound repair. The nanocomposite demonstrates enhanced antibacterial efficacy via combined PDT, PTT, and Cu2+ release, effective immunomodulatory by mild ...
Yihao Sun +9 more
wiley +1 more source
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang +8 more
wiley +1 more source
A photothermal‐responsive engineered platelet‐rich plasma hydrogel (CNB‐ePRP) incorporated with thrombin‐functionalized composite nanobottle was developed, which enables in situ PRP activation, on‐demand growth factor release, multifunctionality, and personalized antimicrobial loading for treatment of diabetic wounds. The CNB‐ePRP hydrogel demonstrated
Wen‐Qiang Qu +8 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source
Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. [PDF]
Chen H +11 more
europepmc +1 more source
This study identifies S100A14 in tumor‐derived exosomes as a key driver of brain metastasis. S100A14 targets PIAS3 in astrocytes, activating STAT3 signaling and promoting immunosuppressive MDSCs recruitment via chemokine secretion. Germacrone, a natural compound, binds S100A14 to disrupt this axis, effectively inhibiting brain metastasis with low ...
Qian Feng +13 more
wiley +1 more source

